Results are in for a new depression drug trial, and they're cratering this stock
Neuroscience company Neumora Therapeutics (NMRA) announced today that its experimental treatment for depression, Navacaprant, fell short of expectations in a late-stage clinical trial, disappointing Wall Street.
Neumora plummets on depression drug data
The well-funded biotech lost most of its value after its drug flunked a late-stage trial. One analyst described the results as a “worst-case scenario for the program.”
Neumora shares slump after depression drug fails in key trial
Neumora Therapeutics' (NMRA.O), opens new tab shares tumbled more than 80% on Thursday after its experimental depression drug failed to reduce symptoms such as sadness and pessimistic thoughts in a key study, raising concerns over the treatment's future ...
Neumora Therapeutics Stock Tanks as Its Depression Drug Misses Goals
Neumora Therapeutics ( NMRA) shares crashed 80% to an all-time low Thursday when the biopharmaceutical firm announced that a late-stage study of its experimental treatment for depression did not meet its goals.
Neumora Plunges After Major Depression Drug Fails in Study
Neumora Therapeutics Inc.’s shares plummeted after the company’s experimental drug failed to show a benefit in a final-stage study for treatment of major depressive disorder.
Neumora Therapeutics’ stock craters after trial of major depressive disorder fails to meet main goals
Neumora Therapeutics Inc.’s stock tumbled 80% Thursday, after the clinical-stage biotech said a late-stage trial of a treatment for major depressive disorder failed to meet its main goals. The Watertown,
Neumora Shares Plunge As Navacaprant Misses Key Endpoints In Major Depressive Disorder Trial
Shares of Neumora Therapeutics, Inc. (NMRA) are down more than 80% at $1.81 in premarket trading Thursday, following the release of
Neumora Therapeutics' depression drug fails to meet main goal of late-stage study
Neumora Therapeutics said on Thursday its experimental drug to treat depression failed to meet the main goal of a late-stage study, sending shares of the company down 82% in premarket trading. The study,
Neumora Therapeutics Study of Depression Treatment Misses Primary, Secondary Endpoints -- Update
Neumora Therapeutics said a study of major depressive disorder treatment navacaprant didn't demonstrate a statistically significant improvement. Shares dived 79% to $2.20 after trading resumed following an earlier halt.
Rolling Out8h
Can depression be treated with magic mushroom or are you just high?
Studies show psilocybin from mushrooms could revolutionize depression treatment offering hope to millions who don't respond to traditional medications.
Scientists Reveal Groundbreaking Nerve Simulation Therapy to Treat Severe Depression
The participants were implanted with a pacemaker-like device, under the skin in the chest that stimulated their left vagus ...
Onlymyhealth7d
THIS Promising Treatment Can Aid In Treating Severe Depression, All You Need To Know About Vagus Nerve Stimulation
Those on the extreme end of the depression spectrum face symptoms that impact their daily activities too and not just their ...
Nerve-stimulation therapy can get people out of severe depression
Participants in clinic trial went from being unable to get out of bed to being productive and interacting with loved ones ...
Scientist Reveals How Stress Triggers Depression Through Inflammation
In a groundbreaking Interview, Professor Raz Yirmiya discusses his innovative research at the intersection of inflammation ...